We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Petrelintide (ZP8396)
An investigational once-weekly long-acting amylin analogue (Zealand Pharma's ZP8396, partnered with Boehringer Ingelheim) being developed for obesity. Honest framing: petrelintide is EARLY-STAGE — the only published human data are two phase-1 (single- and multiple-ascending-dose) trials in which it was well tolerated, had a ~10-day half-life, and produced up to ~8.6% weight loss at 16 weeks. There is NO published phase-2/3 efficacy, durability, or hard-outcome data yet. The optimism for it is largely CLASS-BASED — amylin analogues like cagrilintide and pramlintide cause weight loss — not petrelintide-specific long-term evidence. It is an investigational prescription-pathway drug, not a dietary supplement, and grey-market versions are especially risky.
Prescription medication — not a dietary supplement
Petrelintide is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Petrelintide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2021–2026 with a typical study size of 706 participants.
Based on 5 studies · 2 RCTs · 706 total participants
Confidence
Low confidenceBy outcome
Petrelintide is an investigational early-stage amylin analogue whose only published human data are two phase-1 (single- and multiple-ascending-dose) trials — well tolerated, ~10-day half-life, up to ~8.6% weight loss at 16 weeks. There is no published phase-2/3 efficacy, durability, or hard-outcome data; the optimism is largely class-based (cagrilintide/pramlintide). The thin, early, class-leaning pyramid keeps confidence low.
3 trials ongoing or recruiting · 3 completed on ClinicalTrials.gov
Registered trials show research momentum for Petrelintide, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Petrelintide (developmental code ZP8396) is an investigational, lipidated long-acting analogue of HUMAN amylin — the pancreatic hormone co-secreted with insulin that signals satiety, slows gastric emptying, and reduces food intake.
It is being developed by Zealand Pharma (with Boehringer Ingelheim) as a once-weekly subcutaneous injection for weight management.
Native amylin aggregates rapidly into amyloid fibrils and has a very short half-life, so — like its sibling cagrilintide — petrelintide was engineered for chemical stability and protraction; its medicinal-chemistry development paper describes optimising stability while retaining potency and enabling formulation at near-neutral pH (useful for future co-formulation with other peptides).
The honest evidence picture is that petrelintide is at the TOP of a THIN pyramid.
The only published peer-reviewed human data are two phase-1 trials (single ascending dose and multiple ascending dose, Diabetes Obes Metab 2026): petrelintide was well tolerated with no serious/severe treatment-emergent adverse events, the most common adverse events were mild gastrointestinal ones (nausea 16.7-33.3% vs 16.7% placebo; vomiting and diarrhoea rare), it was slowly absorbed with a ~10-day half-life supporting once-weekly dosing, and it reduced body weight by up to ~8.6% after 16 weeks.
That is a phase-1 safety/PK signal with an encouraging early weight-loss readout — NOT a phase-2/3 efficacy result, and there is no durability, cardiovascular, renal, or mortality outcome data for petrelintide.
Everything beyond those phase-1 trials is class- or analogue-based: the amylin mechanism is well established, and the broader long-acting-amylin class (cagrilintide as monotherapy and in the CagriSema combination, the older short-acting pramlintide) has phase-2/phase-3 weight-loss data.
Reviews of amylin-receptor agonists for obesity name petrelintide alongside eloralintide, Met-233 and AZD6234 as analogues showing 'strong efficacy as monotherapy in clinical trials,' but the published, detailed, peer-reviewed petrelintide dataset remains the phase-1 trials.
Crucially: petrelintide is INVESTIGATIONAL and approved nowhere — it is not a dietary supplement and not an approved medicine, and it is NOT a longevity drug.
The class risks are amylin/GLP-1-style gastrointestinal events (nausea most common, mostly mild and during up-titration) plus injection-site reactions; long-term safety is simply unknown without later-phase trials.
Grey-market 'petrelintide'/'ZP8396' sold online would be an unapproved investigational peptide with no identity, purity, sterility, or dosing guarantee — especially dangerous.
Because it is a prescription-pathway investigational drug rather than a supplement to recommend, it is sandboxed out of goal-based and stack recommendations here, and its score is deliberately LOW to reflect the thin, early, largely class-based evidence base.
Petrelintide is a stabilised, lipidated analogue of human amylin engineered against amyloid aggregation, giving a ~10-day half-life suitable for once-weekly subcutaneous dosing. It agonises amylin receptors (calcitonin-receptor/RAMP heterodimers), the same axis exploited by the short-acting analogue pramlintide and the sibling long-acting analogue cagrilintide.
Amylin signalling acts centrally to induce satiety via homeostatic and hedonic appetite circuits, slows gastric emptying, and suppresses prandial glucagon — reducing food intake and body weight. This is the well-established amylin-class mechanism and the mechanistic basis for petrelintide's weight-loss effect; it is complementary to (not the same as) the GLP-1 pathway.
Petrelintide was deliberately engineered to be stable and formulable at near-neutral pH so it could potentially be co-formulated with other weight-management peptides (e.g. GLP-1 agonists), on the rationale — established for the amylin class — that combining amylin and GLP-1 agonism has additive appetite/weight effects. This is a design intention and class rationale, not yet a proven petrelintide combination outcome.
How Petrelintide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
There is no approved use; obtaining or using grey-market 'petrelintide'/'ZP8396' means taking an unapproved early-phase investigational drug with no clinical oversight, dosing standard, or product-quality guarantee. Strongly discouraged.
Hypoglycemia risk is a class consideration if combined with glucose-lowering agents; petrelintide has not been studied in these combinations. Only relevant under trial-level supervision.
Amylin/incretin-class caution applies; unsupervised use is particularly unwise without long-term safety data.
Contraindicated — not studied; weight-loss pharmacotherapy is avoided in pregnancy.
Amylin-class agonism slows gastric emptying, which can reduce the rate/extent of absorption of co-administered oral drugs — relevant for time-critical or narrow-therapeutic-index oral medicines.
Combining a glucose-lowering/satiety agent with insulin or sulfonylureas can increase hypoglycemia risk; this is a class consideration — petrelintide itself has not been studied in such combinations in published trials.
Petrelintide was engineered for potential co-formulation with GLP-1 agonists, and the amylin class combines additively with GLP-1 in trials. Combining amylin and GLP-1 agonists outside a supervised setting compounds gastrointestinal toxicity and is not appropriate for self-administration.
Tip: Most common adverse event in phase-1 (16.7-33.3% vs 16.7% placebo); dose-related and mitigated by slow escalation. Mostly mild.
Tip: Class-typical GI effects; in phase-1, diarrhoea was rare and vomiting occurred only in the single participant who discontinued.
Tip: Class-typical for once-weekly subcutaneous peptides; rotate injection sites. Long-term incidence not characterised without later-phase data.
Tip: Marked appetite suppression; as with weight-loss pharmacotherapy generally, some of the weight lost may be lean mass — adequate protein and resistance exercise are advised in supervised settings. Not specifically quantified for petrelintide.
Petrelintide has an evidence score of 3.2/10 — emerging evidence based on 5 indexed studies. An investigational once-weekly long-acting amylin analogue (Zealand Pharma's ZP8396, partnered with Boehringer Ingelheim) being developed for obesity. Honest framing: petrelintide is EARLY-STAGE — the only published human data are two phase-1 (single- and multiple-ascending-dose) trials in which it was well tolerated, had a ~10-day half-life, and produced up to ~8.6% weight loss at 16 weeks. There is NO published phase-2/3 efficacy, durability, or hard-outcome data yet. The optimism for it is largely CLASS-BASED — amylin analogues like cagrilintide and pramlintide cause weight loss — not petrelintide-specific long-term evidence. It is an investigational prescription-pathway drug, not a dietary supplement, and grey-market versions are especially risky. Representative study: PMID 34798060.
The commonly studied dose of Petrelintide is Investigational — NO approved dose. Phase-1 trials used single subcutaneous doses of 0.04-2.4 mg and once-weekly subcutaneous dosing escalated every two weeks to target doses of 2.4, 4.8, and 9.0 mg. There is no approved or established regimen; do not self-dose an unapproved drug.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Petrelintide — consistent daily use matters more than the time of day. Phase-1 trials dosed once weekly subcutaneously with gradual dose escalation (every two weeks) to limit gastrointestinal effects; the ~10-day half-life supports once-weekly administration.
Petrelintide should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are nausea, other GI effects (diarrhoea, vomiting), injection-site reactions. Use caution if any of these apply to you: Not a dietary supplement and not an approved drug — investigational; do not self-source grey-market vials; History of pancreatitis (amylin/incretin-class caution); Pregnancy and breastfeeding.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Liraglutide
Mostly mechanism / observationalAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. Included here for reference only; it is NOT a supplement and is not auto-recommended.
Orforglipron
Mostly mechanism / observationalAn investigational ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. Honest appraisal: the phase-2 data are strong and the first phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it is INVESTIGATIONAL and not yet approved as a general weight-loss medicine, has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), and the expected thyroid C-cell class warning and long-term outcomes are unsettled. It is NOT a dietary supplement; listed here for reference only.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 5 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research